Compare Cytokinetics Inc (CYTK) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs JetBlue Airways Corporation — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while JetBlue Airways Corporation trades at $3.89 (market cap $1.48B). The key difference: Cytokinetics Inc is far larger — about 5.8× JetBlue Airways Corporation's market cap, and Cytokinetics Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and JetBlue Airways Corporation for 44 Days on average.
| CYTK | JBLU | |
|---|---|---|
Market Cap | $8.62B | $1.48B |
Volume | 2,594,626 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $87.26 | $6.46 |
52-Week Low | $54.76 | $3.92 |
Typical Hold Time | 19 Days | 44 Days |
Enterprise Value | $8.72B | $8.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
JetBlue (JBLU) trades at $3.97, down 1.49% on the day, with the stock showing bearish technical momentum despite trading near its 52-week low. The company continues to face fundamental challenges with negative net income margins (-9.32% in 2025) and declining revenue trends, though valuation metrics like P/S (0.15) and P/B (0.94) appear attractive. Recent developments include route expansion to Colombia and the launch of BlueFirst premium seating, while activist investor Carl Icahn recently exited board positions per the 2024 agreement.
The outlook remains challenging with persistent losses and high debt levels (debt-to-asset ratio over 50%), though analyst consensus targets $5.89 suggesting potential upside. Key risks include elevated fuel costs, competitive pressures, and ongoing negative cash flow from operations. Investment opportunity exists for value investors betting on operational turnaround, but requires careful risk management given the company's financial strain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
